SG/CALL/MODERNA/125/0.1/20.12.24 | Market Closed - Euronext Paris 10:00:00 27/05/2024 pm IST | ||
| 4.965 EUR | -4.34% |
|
| Current month | +228.99% | ||
| 1 month | +278.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 4.965 | -4.34% |
| 24/24/24 | 5.19 | +7.01% |
| 23/24/23 | 4.85 | +11.24% |
| 22/24/22 | 4.36 | +44.13% |
| 21/24/21 | 3.025 | +1.34% |
Real-time Euronext Paris
Last update May 27, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| 9N19S | |
| ISIN | DE000SU9VRX6 |
| Date issued | 26/02/2024 |
| Strike | 125 $ |
| Maturity | 20/12/2024 (207 Days) |
| Parity | 10 : 1 |
| Emission price | 1.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.24 € |
|---|---|
| Lowest since issue | 0.855 € |
| Spread | 0.05 € |
| Spread % | 1.00% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6
USD
Average target price
138.5
USD
Spread / Average Target
-16.86%
- Stock Market
- Warrants
- 9N19S Warrant
